On October 5, 2020, Eidos Therapeutic, Inc., a Delaware corporation (the Company) and BridgeBio Pharma, Inc., a Delaware corporation
(BridgeBio), issued a joint press release announcing the execution of an Agreement and Plan of Merger, dated as of October 5, 2020, by and among the Company, BridgeBio, Globe Merger Sub I, Inc., a Delaware corporation and an
indirect wholly owned subsidiary of BridgeBio, and Globe Merger Sub II, Inc., a Delaware corporation and an indirect wholly owned subsidiary of BridgeBio (the Merger Agreement), providing for the acquisition of the Company by
BridgeBio. A copy of the press release announcing the execution of the Merger Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Joint Press Release, dated October 5, 2020
|
Forward-Looking Statements
This communication contains forward-looking statements relating to the proposed transaction involving the Company and BridgeBio, including financial estimates
and statements as to the expected timing, completion and effects of the proposed transaction. Statements in this press release that are not statements of historical fact are considered forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words
such as anticipates, believes, continues, could, estimates, expects, intends, may, plans, potential, predicts,
projects, seeks, should, will, and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking
statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements are neither
forecasts, promises nor guarantees, and are based on the current beliefs of the Companys management and BridgeBios management as well as assumptions made by and information currently available to the Company and BridgeBio. Such
statements reflect the current views of the Company and BridgeBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions
about the Company and BridgeBio, including, without limitation, (i) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement, (ii) the risk that the Companys and/or
BridgeBios stockholders may not approve the proposed transaction, (iii) inability to complete the proposed transaction because, among other reasons, conditions to the closing of the proposed transaction may not be satisfied or waived,
(iv) uncertainty as to the timing of completion of the proposed transaction, (v) potential adverse effects or changes to relationships with customers, employees, suppliers or other parties resulting from the announcement or completion of
the proposed transaction, (vi) potential litigation relating to the proposed transaction that could be instituted against the Company, BridgeBio or their respective directors and officers, including the effects of any outcomes related thereto,
(vii) possible disruptions from the proposed transaction that could harm the Companys or BridgeBios business, including current plans and operations, (viii) unexpected costs, charges or expenses resulting from the proposed
transaction, (ix) uncertainty of the expected financial performance of each of the Company and BridgeBio following completion of the proposed transaction, including the possibility that the expected synergies and value creation from the
proposed transaction will not be realized or will not be realized within the expected time period, (x) the ability of the Company and/or BridgeBio to implement their respective business strategies, (xi) the ability of each of the Company
or BridgeBio to continue its planned preclinical and clinical development of its respective development programs, and the timing and success of any such continued preclinical and clinical development and planned regulatory submissions,
(xii) the potential therapeutic and clinical benefits of acoramidis, (xiii) inability to retain and hire key personnel and (xiv) the unknown future impact of the COVID-19 pandemic
delay on certain clinical trial milestones and/or the Companys or
2